基底细胞痣综合征患者中抑制hedgehog通路:多中心、随机、双盲、安慰剂对照2期试验的最终结果
这项多中心随机双盲安慰剂对照2期试验纳入41例基底细胞痣综合征患者,比较口服vismodegib 150 mg/日与安慰剂对治疗后3个月新发可手术基底细胞癌发生率的影响,并设开放标签延长期随访至36个月。Vismodegib组新发可手术基底细胞癌年发生率显著低于安慰剂组,但不良反应常导致治疗中断,中断后基底细胞癌复发。
要点
- Vismodegib组新发可手术基底细胞癌每人每年2个(SD 0·12)vs 安慰剂组34个(SD 1·32),p<0·0001。
- 18例中仅3例(17%)能连续耐受vismodegib满36个月。
- 持续用药者新发可手术基底细胞癌少于中断用药者(每人每年0·6 vs 1·7,p<0·0001)。
核心结论
- Vismodegib可降低基底细胞痣综合征患者的基底细胞癌肿瘤负荷。
- Vismodegib相关不良事件常导致治疗中断,中断后出现基底细胞癌复发。
研究设计与样本
- 多中心、随机、双盲、安慰剂对照2期试验,纳入年龄35-75岁、至少有10个可手术基底细胞癌的基底细胞痣综合征患者,按2:1随机分配至vismodegib或安慰剂。
- 主试验41例,口服vismodegib 150 mg/日或安慰剂,主要终点为治疗3个月后新发可手术基底细胞癌的发生率,按改良意向治疗分析。
- 随后开放标签期37例继续vismodegib,其中两个中心用药至第36个月(25例),第三个中心监测至第36个月(12例)。
- 每3个月随访一次,最长36个月;试验注册号ClinicalTrials.gov NCT00957229。
主要发现
- 2009年9月22日至2011年1月24日纳入41例,中位监测36个月(IQR 36-36)。
- Vismodegib组(26例)新发可手术基底细胞癌每人每年2个(SD 0·12)vs 安慰剂组(15例)34个(SD 1·32),p<0·0001。
- 初始安慰剂组11例交叉至vismodegib后,新发可手术基底细胞癌每人每年0·4个(SD 0·2)vs 安慰剂期30·0个(SD 7·8),p<0·0001。
- 持续用药者新发可手术基底细胞癌每人每年0·6个(SD 0·72)vs 中断用药者1·7个(SD 1·8),p<0·0001。
- 治疗相关3-4级不良事件包括体重下降20%或以上(6例)和肌肉痉挛(2例);试验期间2例死亡,分别死于喉癌和转移性前列腺癌,判定可能与药物无关。
关键数值与推荐
- 口服vismodegib 150 mg/日与安慰剂比较。
- 仅3例(17%)18例患者连续耐受vismodegib满36个月。
- 持续用药与中断用药的新发可手术基底细胞癌比较:每人每年0·6个(SD 0·72)vs 1·7个(SD 1·8),p<0·0001。
- 初始安慰剂组交叉用药前后比较:每人每年0·4个(SD 0·2)vs 30·0个(SD 7·8),p<0·0001。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Aberrant hedgehog signalling underlies the development of basal-cell carcinomas. We previously reported the interim analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial in patients with the basal-cell nevus (Gorlin) syndrome indicating that the smoothened inhibitor vismodegib reduces basal-cell carcinoma tumour burden and prevents new basal-cell carcinoma growth in patients with basal-cell nevus syndrome. We report the final results of this 36 month trial. METHODS: In our multicentre, randomised, double-blind, placebo-controlled, phase 2 trial we enrolled patients aged 35-75 years with basal-cell nevus syndrome with at least ten surgically eligible basal-cell carcinomas at the Children's Hospital Oakland, Columbia University outpatient dermatology clinic (NY, USA) and a private practice outpatient dermatology office in Newport Beach (CA, USA). Patients were assigned to vismodegib or placebo (2:1) according to a randomisation sequence generated by computer code. The primary endpoint of the trial of 41 patients was to compare the effect of oral vismodegib (150 mg/day) versus placebo on the incidence of new surgically eligible basal-cell carcinomas after 3 months of treatment. In the subsequent, open-label phase (n=37) patients continued vismodegib at two sites for as long as month 36 (n=25) and at the third site were monitored up to month 36 (n=12). Additional endpoints for this phase were: whether continuous versus interrupted dosing differentially affected tumour burden; time to reach various levels of reduction in tumour burden; reduction in tumour size in patients who took less than 50% of the expected number of vismodegib tablets; reduction in the number of surgical excisions required per year before, during, and after treatment; and the effect of vismodegib on hedgehog target gene expression. We monitored patients at visits every 3 months for up to 36 months. The primary endpoint was analysed on a modified intention-to-treat basis. This trial is registered with ClinicalTrials.gov, number NCT00957229. FINDINGS: Between Sept 22, 2009, and Jan 24, 2011, 41 patients were monitored for a median of 36 months (IQR 36-36). Patients treated with vismodegib (n=26) had a mean reduced rate of new surgically eligible basal-cell carcinomas compared with patients randomly assigned to placebo (n=15; two [SD 0·12] new surgically eligible basal-cell carcinomas per patient per year vs 34 [1·32] new surgically eligible basal-cell carcinomas per patient per year, p<0·0001). In the 11 patients initially assigned to placebo, mean cross over to vismodegib reduced the development of new surgically eligible basal-cell carcinomas compared with placebo (0·4 [SD 0·2] new surgically eligible basal-cell carcinomas per patient per year vs 30·0 [7·8] new surgically eligible basal-cell carcinomas per patient per year, p<0·0001). Only three (17%) of 18 patients tolerated vismodegib continuously for the full 36 months. Fewer new surgically eligible basal-cell carcinomas developed in patients receiving vismodegib continuously than in those who interrupted dosing (mean 0·6 [0·72] new surgically eligible basal-cell carcinomas per patient per year vs 1·7 [1·8] new surgically eligible basal-cell carcinomas per patient per year, p<0·0001). Treatment-related grade 3-4 adverse events included weight loss of 20% or more (n=6) and muscle cramps (n=2). Two patients died during the course of the trial, one each from laryngeal and metastatic prostate cancer, deemed probably unrelated to drug. INTERPRETATION: Vismodegib reduces basal-cell carcinoma tumour burden in patients with basal-cell nevus syndrome. Adverse events associated with vismodegib frequently led to interruption of treatment, which is followed by basal-cell carcinoma recurrence. FUNDING: Genentech investigator-initiated trial funding, Clinical and Translational Science Award from the National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Cancer Institute, Damon Runyon Cancer Research Foundation Clinical Investigator Award, Swim across America Foundation, and Michael J Rainen Family Foundation.
引用
- Tang JY, Ally MS, Chanana AM, et al. Inhibition of the hedgehog pathway in patients with basal-cell nevus syndrome: final results from the multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2016. PMID: 27838224. doi:10.1016/S1470-2045(16)30566-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。